articleTop 1% cited
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Journal of Clinical Oncology · 2002 · Vol. 20(3) · pp. 719–726
Charles L. Vogel✉(Sylvester Comprehensive Cancer Center)
Abstract
Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.
HER2/EGFR in Cancer ResearchPeptidase Inhibition and AnalysisMonoclonal and Polyclonal Antibodies ResearchMedicineTrastuzumabChillsBreast cancerMetastatic breast cancerInternal medicineDiscontinuationAdverse effectCancerHazard ratio
MeSH terms
TrastuzumabAdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic AgentsBreast NeoplasmsFemaleGene AmplificationHumansImmunohistochemistryMiddle AgedQuality of LifeSafetyTreatment Outcome
Citations
2,949
FWCI
66.37
field-weighted impact
References
10
Percentile
100%
vs. same field & year
Citations per year
Cited by
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Oncotarget · 2016 · 325 citations
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
Breast Cancer Research and Treatment · 2008 · 802 citations
Breast cancer in China
The Lancet Oncology · 2014 · 1,405 citations
Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
Frontiers in Oncology · 2012 · 604 citations
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Cancer Cell · 2004 · 1,856 citations
Protein therapeutics: a summary and pharmacological classification
Nature Reviews Drug Discovery · 2007 · 2,066 citations
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
Cancer Cell · 2006 · 1,315 citations
Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?
BMC Cancer · 2009 · 368 citations
References
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene
Science · 1987 · 11,680 citations
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Journal of Clinical Oncology · 1999 · 2,788 citations
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
JNCI Journal of the National Cancer Institute · 1993 · 15,705 citations
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
New England Journal of Medicine · 2001 · 11,439 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.